Stocks / NASDAQ / Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc.

Our Opinion

Mineralys Therapeutics Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Company Description

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Company Website: